XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
22. Oktober 2024 08:00 ET
|
XOMA Corporation
XOMA Royalty acquires 50% economic interest in portfolio of 60-plus early-stage assets with $15M payment to Twist Bioscience
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
23. September 2024 06:30 ET
|
XOMA Corporation
MIPLYFFA(TM) becomes 6th commercial asset in XOMA Royalty's portfolio
XOMA Declares Quarterly Preferred Stock Dividends
20. Juni 2024 07:30 ET
|
XOMA Corporation
July 2024 Dividends
King and Queen of the Netherlands to pay working visit to United States: Georgia and New York – program
28. Mai 2024 16:22 ET
|
Embassy of the Kingdom of the Netherlands
Washington, D.C., May 28, 2024 (GLOBE NEWSWIRE) -- His Majesty King Willem-Alexander and Her Majesty Queen Máxima are to travel to the United States for a working visit to the states of Georgia and...
XOMA Corporation Announces Closing of Tender Offer
03. April 2024 09:00 ET
|
XOMA Corporation
XOMA completes acquisition of Kinnate.
Donkin Mine Regulator Approves Phase II Report
14. März 2024 07:00 ET
|
Morien Resources Corp.
HALIFAX, Nova Scotia, March 14, 2024 (GLOBE NEWSWIRE) -- Morien Resources Corp. ("Morien" or the "Company") (TSX-V:MOX), today provides an update on the Donkin Coal Mine (“Donkin” or the “Mine”) in...
Morien Announces Renewal of Normal Course Issuer Bid
31. Januar 2024 10:45 ET
|
Morien Resources Corp.
HALIFAX, Nova Scotia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Morien Resources Corp. ("Morien" or the "Company") (TSX-V:MOX), is pleased to announce that the TSX Venture Exchange ("TSX-V") accepted the...
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
11. Januar 2024 16:05 ET
|
XOMA Corporation
EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that based upon the U.S. Food and Drug Administration’s (FDA)...
NOTICE TO DISREGARD -- The Royal Elites, Inc.
02. Januar 2024 11:49 ET
|
The Royal Elites, Inc.
Royal Saudi Princess Ameriah Al Saud Announces Plans for Philanthropic Giving
XOMA Announces Stock Repurchase Program of up to $50 Million
02. Januar 2024 07:30 ET
|
XOMA Corporation
XOMA to repurchase up to $50M of its stock before January 2027. Management actively participating in capital structure to maximize shareholder value.